Two synthetic GHRH peptide analogs protected newborn rat heart cells from radiation damage by reducing oxidative stress without affecting normal cell function.
10–100 nMconcentration range at which GHRH agonist JI-34 protected heart cells from radiation damage
What the researchers found
GHRH agonists JI-34 and MR-356 significantly improved viability of irradiated neonatal rat cardiac myocytes and reduced radiation-induced reactive oxygen species (ROS) levels. JI-34 showed protective effects at 10 and 100 nM concentrations, while MR-356 was protective at 500 nM. JI-34 also interfered with the activation of SAFE/RISK signaling pathways. Notably, neither compound affected cell viability or proliferation in unirradiated cells, suggesting a radiation-specific protective mechanism.
Why it matters
Radiation-induced cardiac damage is a clinically significant but poorly understood side effect of cancer radiotherapy. With limited options to protect the heart during treatment, these GHRH peptide analogs represent a potential new class of cardioprotective agents that could improve quality of life for cancer patients receiving chest radiation.
The numbers in context
10 Gy radiation dose · JI-34 protective at 10 and 100 nM · MR-356 protective at 500 nM · 52 kDa GHRHR protein isoform detected
How the study worked
Cardiac myocytes isolated from newborn rats were cultured and exposed to 10 Gy of radiation. Researchers then tested two synthetic GHRH agonist peptides (JI-34 and MR-356) at various concentrations, measuring cell viability, proliferation, reactive oxygen species levels, signaling pathway activation, and GHRH receptor protein expression via Western blot.
Who was studied
Neonatal rat ventricular myocyte cell cultures (in vitro)
What this study cannot tell us
This was an in vitro study using neonatal rat heart cells, which may behave differently from adult human cardiac tissue. The radiation-specific protective mechanism needs validation in animal models before any clinical relevance can be assessed. Long-term effects and optimal dosing remain unknown.
How to read the evidence
This is an in vitro cell culture study using neonatal rat cardiac myocytes. While it demonstrates clear protective effects, it represents early preclinical evidence that requires validation in animal models and eventually human studies.
When this study was published
Published in 2016, this study laid groundwork for exploring GHRH agonists as cardioprotective agents. Follow-up in vivo studies would be needed to advance this concept toward clinical application.
The bigger picture
Cardiotoxicity from cancer treatment is a growing concern as survival rates improve. Peptide-based cardioprotective agents like GHRH agonists represent an emerging strategy to shield the heart during radiotherapy. This early-stage research adds to a broader effort to develop supportive therapies that minimize collateral damage from cancer treatment.
Questions still open
- Do these GHRH peptide analogs show the same cardioprotective effects in live animal models of radiation-induced heart damage?
- Could GHRH agonists protect adult human cardiac tissue, which differs significantly from neonatal rat cells?
- Would these peptides interfere with the anticancer effects of radiation therapy if used as protective agents?
Common questions
What are GHRH agonists and how might they protect the heart?
Why is radiation-induced heart damage a concern in cancer treatment?
Read the original research
Protection of neonatal rat cardiac myocytes against radiation-induced damage with agonists of growth hormone-releasing hormone.
Pharmacological research, 111, 859-866
Citation
Kiscsatári, Laura; Varga, Zoltán; Schally, Andrew V; Gáspár, Renáta; Nagy, Csilla Terézia; Giricz, Zoltán; Ferdinandy, Péter; Fábián, Gabriella; Kahán, Zsuzsanna; Görbe, Anikó. (2016). Protection of neonatal rat cardiac myocytes against radiation-induced damage with agonists of growth hormone-releasing hormone.. Pharmacological research, 111, 859-866. https://doi.org/10.1016/j.phrs.2016.07.036